The study of mechanisms of protective effect of rg1 against arthritis by inhibiting osteoclast differentiation and maturation in cia mice

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Gu, Yanqing ^a   Fan, Weimin ^a   Yin, Guoyong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALCIAN BLUE; CALCITONIN RECEPTOR; CATHEPSIN K; GELATINASE B; GINSENOSIDE RG 1; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; PROTEIN C JUN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR RELA; GINSENOSIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANKLE; ARTICLE; ARTICULAR CARTILAGE; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROXIMAL INTERPHALANGEAL JOINT; RHEUMATOID ARTHRITIS; WESTERN BLOTTING; ANIMAL; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; DRUG EFFECT; EXPERIMENTAL ARTHRITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL DIFFERENTIATION; CELL LINE; GINSENOSIDES; MALE; MICE; OSTEOCLASTS;

EID: 84907228818     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/305071     Document Type: Article

References (51)

1. Ngian G. S., Rheumatoid arthritis. Australian Family Physician 2010 39 9 626 628 2-s2.0-77957374843
2. Silman A. J., Pearson J. E., Epidemiology and genetics of rheumatoid arthritis. Arthritis Research & Therapy 2002 4, supplement 3 S265 S272
3. Pettit A. R., Ji H., Von Stechow D., Müller R., Goldring S. R., Choi Y., Benoist C., Gravallese E. M., TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. The American Journal of Pathology 2001 159 5 1689 1699 10.1016/S0002-9440(10)63016-7 2-s2.0-0035153246
4. Redlich K., Hayer S., Ricci R., David J., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J. S., Wagner E. F., Schett G., Osteoclasts are essential for TNF- α -mediated joint destruction. Journal of Clinical Investigation 2002 110 10 1419 1427 10.1172/JCI200215582 2-s2.0-0036853902
5. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M. T., Martin T. J., Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrine Reviews 1999 20 3 345 357 10.1210/edrv.20.3.0367 2-s2.0-0033304730
6. Schett G., Cells of the synovium in rheumatoid arthritis: osteoclasts. Arthritis Research and Therapy 2007 9 1 article 203 10.1186/ar2110 2-s2.0-34247589636
7. Bromley M., Woolley D. E., Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. Arthritis and Rheumatism 1984 27 8 857 863 10.1002/art.1780270804 2-s2.0-0021133558
8. Suzuki Y., Tsutsumi Y., Nakagawa M., Suzuki H., Matsushita K., Beppu M., Aoki H., Ichikawa Y., Mizushima Y., Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. Rheumatology 2001 40 6 673 682 10.1093/rheumatology/40.6.673 2-s2.0-0034940854
9. Redlich K., Hayer S., Ricci R., David J., Tohidast-Akrad M., Kollias G., Steiner G., Smolen J. S., Wagner E. F., Schett G., Osteoclasts are essential for TNF- α -mediated joint destruction. The Journal of Clinical Investigation 2002 110 10 1419 1427 10.1172/JCI200215582 2-s2.0-0036853902
10. Karmakar S., Kay J., Gravallese E. M., Bone Damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheumatic Disease Clinics of North America 2010 36 2 385 404 10.1016/j.rdc.2010.03.003 2-s2.0-77953261340
11. Cohen S. B., Valen P., Ritchlin C., RANKL inhibition with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: month 6 MRI results. Arthritis & Rheumatology 2006 54 9
12. Ishii M., Egen J. G., Klauschen F., Meier-Schellersheim M., Saeki Y., Vacher J., Proia R. L., Germain R. N., Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009 458 7237 524 528 10.1038/nature07713 2-s2.0-63649143900
13. Liu P., Yin H., Xu Y., Zhang Z., Chen K., Li Y., Effects of ginsenoside Rg1 on postimplantation rat and mouse embryos cultured in vitro. Toxicology in Vitro 2006 20 2 234 238 10.1016/j.tiv.2005.06.029 2-s2.0-30644459366
14. Jia L., Wang W., Zhou L., Mo F., Li M., Antimotion sickness effects of ginsenosides combined with dexamethasone in rats. Journal of Chinese Integrative Medicine 2010 8 4 358 362 10.3736/jcim20100410 2-s2.0-77950881267
15. 1effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Research 2004 1021 1 41 53 10.1016/j.brainres.2004.06.030 2-s2.0-4344622460
16. Lee Y. J., Chung E., Youl Lee K., Hee Lee Y., Huh B., Lee S. K., Ginsenoside-Rg1, one of the major active molecules from Panax ginseng, is a functional ligand of glucocorticoid receptor. Molecular and Cellular Endocrinology 1997 133 2 135 140 10.1016/S0303-7207(97)00160-3 2-s2.0-0030838299
17. Chan R. Y. K., Chen W.-F., Dong A., Guo D., Wong M.-S., Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. The Journal of Clinical Endocrinology & Metabolism 2002 87 8 3691 3695 10.1210/jc.87.8.3691 2-s2.0-0036345583
18. Kim H. A., Kim S., Chang S. H., Hwang H. J., Choi Y., Anti-arthritic effect of ginsenoside Rb1 on collagen induced arthritis in mice. International Immunopharmacology 2007 7 10 1286 1291 10.1016/j.intimp.2007.05.006 2-s2.0-34547190184
19. Chang S., Choi Y., Park J., Jung D., Shin J., Yang J., Ko S., Kim S., Kim J., Anti-inflammatory effects of BT-201, an n -butanol extract of Panax notoginseng, observed in vitro and in a collagen-induced arthritis model. Clinical Nutrition 2007 26 6 785 791 10.1016/j.clnu.2007.07.008 2-s2.0-36148941379
20. Choi Y. S., Kang E. H., Lee E. Y., Gong H. S., Kang H. S., Shin K., Lee E. B., Song Y. W., Lee Y. J., Joint-protective effects of compound K, a major ginsenoside metabolite, in rheumatoid arthritis: in vitro evidence. Rheumatology International 2013 33 8 1981 1990 10.1007/s00296-013-2664-9 2-s2.0-84880917448
21. Rhule A., Rase B., Smith J. R., Shepherd D. M., Toll-like receptor ligand-induced activation of murine DC2.4 cells is attenuated by Panax notoginseng. Journal of Ethnopharmacology 2008 116 1 179 186 10.1016/j.jep.2007.11.019 2-s2.0-38649124341
22. Sun K., Wang C. S., Guo J., Horie Y., Fang S., Wang F., Liu Y., Liu L., Yang J., Fan J., Han J., Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. Life Sciences 2007 81 6 509 518 10.1016/j.lfs.2007.06.008 2-s2.0-34547405823
23. Wu C. F., Bi X. L., Yang J. Y., Zhan J. Y., Dong Y. X., Wang J. H., Wang J. M., Zhang R., Li X., Differential effects of ginsenosides on NO and TNF- α production by LPS-activated N9 microglia. International Immunopharmacology 2007 7 3 313 320 10.1016/j.intimp.2006.04.021 2-s2.0-33846618796
24. Du J., Cheng B., Zhu X., Ling C., Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid efficacy with reduced side effects. The Journal of Immunology 2011 187 2 942 950 10.4049/jimmunol.1002579 2-s2.0-79960481117
25. King T. J., Georgiou K. R., Cool J. C., Scherer M. A., Ang E. S. M., Foster B. K., Xu J., Xian C. J., Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF- B activation. The American Journal of Pathology 2012 181 1 121 129 10.1016/j.ajpath.2012.03.037 2-s2.0-84862680801
26. Kaji H., Sugimoto T., Kanatani M., Nishiyama K., Chihara K., Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. Journal of Bone and Mineral Research 1997 12 5 734 741 10.1359/jbmr.1997.12.5.734 2-s2.0-0030969096
27. Okamoto K., Takayanagi H., Osteoclasts in arthritis and Th17 cell development. International Immunopharmacology 2011 11 5 543 548 10.1016/j.intimp.2010.11.010 2-s2.0-79954634320
28. Broadhead M. L., Clark J. C., Dass C. R., Choong P. F., Myers D. E., Therapeutic targeting of osteoclast function and pathways. Expert Opinion on Therapeutic Targets 2011 15 2 169 181 10.1517/14728222.2011.546351 2-s2.0-78651367559
29. Shen Y., Li Y., Li S., Ma L., Ding L., Ji H., Alleviation of ovariectomy-induced osteoporosis in rats by Panax notoginseng saponins. Journal of Natural Medicines 2010 64 3 336 345 10.1007/s11418-010-0416-7 2-s2.0-77953621304
30. Peng L. H., Ko C. H., Siu S. W., Koon C. M., Yue G. L., Cheng W. H., Lau T. W., Han Q. B., Ng K. M., Fung K. P., Lau C. B. S., Leung P. C., In vitro & in vivo assessment of a herbal formula used topically for bone fracture treatment. Journal of Ethnopharmacology 2010 131 2 282 289 10.1016/j.jep.2010.06.039 2-s2.0-77956265939
31. Anusaksathien O., Laplace C., Li X., Ren Y., Peng L., Goldring S. R., Galson D. L., Tissue-specific and ubiquitous promoters direct the expression of alternatively spliced transcripts from the calcitonin receptor gene. The Journal of Biological Chemistry 2001 276 25 22663 22674 10.1074/jbc.M007104200 2-s2.0-0035933788
32. Motyckova G., Weilbaecher K. N., Horstmann M., Rieman D. J., Fisher D. Z., Fisher D. E., Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proceedings of the National Academy of Sciences of the United States of America 2001 98 10 5798 5803 10.1073/pnas.091479298 2-s2.0-0035826866
33. Reddy S. V., Hundley J. E., Windle J. J., Alcantara O., Linn R., Leach R. J., Boldt D. H., Roodman G. D., Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter. Journal of Bone and Mineral Research 1995 10 4 601 606 2-s2.0-0028915294
34. Choi H. J., Park Y. R., Nepal M., Choi B., Cho N., Choi S. H., Heo S. R., Kim H. S., Yang M., Soh Y., Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF- Κ B signaling pathways. European Journal of Pharmacology 2010 636 1-3 28 35 10.1016/j.ejphar.2010.03.023 2-s2.0-77952672479
35. Karin M., Yamamoto Y., Wang Q. M., The IKK NF- B system: a treasure trove for drug development. Nature Reviews Drug Discovery 2004 3 1 17 26 10.1038/nrd1279 2-s2.0-0346505340
36. Novack D. V., Role of NF- B in the skeleton. Cell Research 2011 21 1 169 182 10.1038/cr.2010.159 2-s2.0-78650858041
37. Boyle W. J., Simonet W. S., Lacey D. L., Osteoclast differentiation and activation. Nature 2003 423 6937 337 342 10.1038/nature01658 2-s2.0-0037673945
38. Lee Z. H., Kim H.-H., Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochemical and Biophysical Research Communications 2003 305 2 211 214 10.1016/S0006-291X(03)00695-8 2-s2.0-0038706164
39. Monje P., Hernández-Losa J., Lyons R. J., Castellone M. D., Gutkind J. S., Regulation of the transcriptional activity of c-Fos by ERK: a novel role for the prolyl isomerase Pin1. The Journal of Biological Chemistry 2005 280 42 35081 35084 10.1074/jbc.C500353200 2-s2.0-27444440554
40. Ang E., Liu Q., Qi M., Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF- B and ERK. Journal of Cellular Biochemistry 2011 112 1 89 97 10.1002/jcb.22800
41. Kim H. J., Lee Y., Chang E. J., Kim H., Hong S., Zang H. L., Ryu J., Suppression of osteoclastogenesis by N,N-dimethyl-D-erythros-phingosine: a sphingosine kinase inhibition-independent action. Molecular Pharmacology 2007 72 2 418 428 10.1124/mol.107.034173 2-s2.0-34547207232
42. Ikeda F., Nishimura R., Matsubara T., Tanaka S., Inoue J., Reddy S. V., Hata K., Yamashita K., Hiraga T., Watanabe T., Kukita T., Yoshioka K., Rao A., Yoneda T., Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-requlated osteoclast differentiation. The Journal of Clinical Investigation 2004 114 4 475 484 10.1172/JCI200419657 2-s2.0-4344697340
43. Matsumoto M., Sudo T., Saito T., Osada H., Tsujimoto M., Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF- B ligand (RANKL). The Journal of Biological Chemistry 2000 275 40 31155 31161 10.1074/jbc.M001229200 2-s2.0-0034613188
44. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J., Wagner E. F., Mak T. W., Kodama T., Taniguchi T., Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Developmental Cell 2002 3 6 889 901 10.1016/S1534-5807(02)00369-6 2-s2.0-18744366041
45. Kim Y., Sato K., Asagiri M., Morita I., Soma K., Takayanagi H., Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. The Journal of Biological Chemistry 2005 280 38 32905 32913 10.1074/jbc.M505820200 2-s2.0-25444444351
46. Matsumoto M., Kogawa M., Wada S., Takayanagi H., Tsujimoto M., Katayama S., Hisatake K., Nogi Y., Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. The Journal of Biological Chemistry 2004 279 44 45969 45979 10.1074/jbc.M408795200 2-s2.0-8544267975
47. Matsuo K., Galson D. L., Zhao C., Peng L., Laplace C., Wang K. Z. Q., Bachler M. A., Amano H., Aburatani H., Ishikawa H., Wagner E. F., Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. The Journal of Biological Chemistry 2004 279 25 26475 26480 10.1074/jbc.M313973200 2-s2.0-2942731511
48. Jimi E., Nakamura I., Amano H., Taguchi Y., Tsurukai T., Tamura M., Takahashi N., Suda T., Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology 1996 137 8 2187 2190 2-s2.0-34347367005
49. Hirayama T., Danks L., Sabokbar A., Athanasou N. A., Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology 2002 41 11 1232 1239 10.1093/rheumatology/41.11.1232 2-s2.0-0036853230
50. Chen F., Ouyang Y., Ye T., Estrogen inhibits RANKL-induced osteoclastic differentiation by increasing the expression of TRPV5 channel. Journal of Cellular Biochemistry 2014 115 4 651 658
51. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., Morita I., Wagner E. F., Mak T. W., Serfling E., Takayanagi H., Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. Journal of Experimental Medicine 2005 202 9 1261 1269 10.1084/jem.20051150 2-s2.0-27744432009